Central retinal vein occlusion (CRVO)

圖片_視網膜中央靜脈阻塞_視力模糊_CRVO

Central retinal vein occlusion, also known as CRVO, is a condition in which part or all of the main vein that carries blood away from the retina becomes blocked. This can cause blurred vision and other eye problems.

Reasons

Most CRVO patients develop it in one eye. Moreover, although diabetes and high blood pressure are risk factors for CRVO, the exact cause is still unknown. What we do know is that CRVO is caused by a clot or a reduction in the flow of blood to the central retinal vein, which then drains the retina.

The occurrence of CRVO in both eyes may be associated with systemic diseases; in these cases, the tendency for blood to coagulate abnormally is more common, leading to the detection of so-called “hypercoagulable states.”

Diagnostic tests

CRVO is usually a clinical diagnosis, that is, a diagnosis based on medical signs and symptoms reported by the patient. When the retina specialist looks at the eye, a typical retinal hemorrhage (bleeding) phenomenon occurs, and a diagnosis is made (Figure 1). Common conditions that cause CRVO include diabetic macular edema (macular disease) and retinal diseases associated with low blood count, such as anemia and platelet deficiency (thrombocytopenia).

圖片_光學相干斷層掃描測量黃斑水腫腫脹
Optical coherence tomography measures the extent of macular edema.
圖片_診斷測試​_異常血管_熒光血管
Fluorescence vascular imaging seeks the growth of new abnormal blood vessels

Treatment and prognosis

圖片_視網膜病變_治療_眼球_注射_有效時間
  • CRVO has a better prognosis in younger people. In older patients who have not undergone treatment, about one-third improve on their own, about one-third remain unchanged with aging, and about one-third worsen.
  • Patients with CRVO have elevated vascular endothelial growth factor (VEGF); this leads to macular edema and new blood vessels that are prone to bleeding.
  • The most common treatment method is the periodic injection of anti-VEGF medications into the eye to reduce the growth and swelling of new blood vessels. Anti-VEGF medications include bevacizumab (Avastin®), ranibizumab (Lucentis®), and aflibercept (Eylea®).
  • Long-acting steroid therapy for persistent macular edema
圖片_視網膜激光光凝緩解周邊性視網膜缺血_治療與預後​
Laser photocoagulation of the retina alleviates peripheral retinal ischemia